Trending NewsTrending NewsNASDAQ:UTHR United Therapeutics (UTHR) Stock Price, News & Analysis $587.50 +2.71 (+0.46%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$592.41 +4.91 (+0.84%) As of 10/23/2026 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About United Therapeutics Stock (NASDAQ:UTHR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get United Therapeutics alerts:Sign Up Key Stats Today's Range$576.24▼$590.9850-Day Range$472.21▼$587.5052-Week Range$409.07▼$609.35Volume621,320 shsAverage Volume926,008 shsMarket Capitalization$25.20 billionP/E Ratio21.02Dividend YieldN/APrice Target$650.43Consensus RatingModerate Buy Company Overview United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company’s portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH. The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer. United Therapeutics sells its products through healthcare providers and specialty pharmacies, primarily in the United States, with selected products available in international markets subject to local regulatory approvals. Founded in 1996 by Martine Rothblatt, United Therapeutics has expanded beyond pharmaceutical development into organ manufacturing and transplantation research. Through subsidiaries and affiliated operations, including Lung Biotechnology and Revivicor, the company is working on technologies intended to increase the availability of transplantable lungs and other organs, including regenerative medicine and genetically engineered animal organs. Rothblatt serves as the company’s chairperson and chief executive officer.AI Generated. May Contain Errors. Read More United Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks84th Percentile Overall ScoreUTHR MarketRank™: 4.18454935622 of 5 starsUnited Therapeutics scored higher than 84% of companies evaluated by MarketBeat, and ranked 82nd out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingModerate Buy Consensus RatingUnited Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on no strong buy ratings, 12 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialUnited Therapeutics has a consensus price target of $650.43, representing about 10.7% upside from its current price of $587.50.Amount of Analyst CoverageUnited Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about United Therapeutics' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth16.46% Earnings GrowthEarnings for United Therapeutics are expected to grow by 16.46% in the coming year, from $26.07 to $30.36 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of United Therapeutics is 21.02, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.38.Price to Earnings Ratio vs. SectorThe P/E ratio of United Therapeutics is 21.02, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.05.Price to Earnings Growth RatioUnited Therapeutics has a PEG Ratio of 4.26. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioUnited Therapeutics has a P/B Ratio of 3.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about United Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.18% of the float of United Therapeutics has been sold short.Short Interest Ratio / Days to CoverUnited Therapeutics has a short interest ratio ("days to cover") of 3.61, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in United Therapeutics has recently increased by 28.44%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldUnited Therapeutics does not currently pay a dividend.Dividend GrowthUnited Therapeutics does not have a long track record of dividend growth. News and Social Media4.2 / 5News Sentiment0.70 News SentimentUnited Therapeutics has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 31 news articles for United Therapeutics this week, compared to 11 articles on an average week.Search Interest14 people have searched for UTHR on MarketBeat in the last 30 days. This is an increase of 367% compared to the previous 30 days.MarketBeat Follows8 people have added United Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, United Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $208,338,661.00 in company stock.Percentage Held by Insiders8.60% of the stock of United Therapeutics is held by insiders.Percentage Held by Institutions94.08% of the stock of United Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about United Therapeutics' insider trading history. Receive UTHR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. UTHR Stock News HeadlinesUnited Therapeutics (NASDAQ:UTHR) to Buy Back $2.00 billion in StockOctober 24 at 1:13 AM | americanbankingnews.comAnalysts Conflicted on These Healthcare Names: United Therapeutics (UTHR), Elevance Health (ELV) and Abbott Laboratories (ABT)October 23 at 1:19 PM | theglobeandmail.comThe $100 Stock Behind Elon's Next MoveA small, publicly traded supplier trading under $100 a share has reportedly worked alongside Elon Musk for more than a decade. A federal filing may outline Musk's next major move: an AI network of up to a million satellites powered by the sun. James Altucher says this supplier holds the piece Musk doesn't own.October 25 at 1:00 AM | Paradigm Press (Ad)Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $5,161,540.00 in StockOctober 23 at 4:09 AM | americanbankingnews.comUnited Therapeutics' Tyvaso Outlook Faces Near-Term Pressure After Liquidia Settlement, RBC SaysOctober 22 at 2:57 PM | finance.yahoo.comUnited Therapeutics Corporation announces an Equity Buyback for $2,000 million worth of its shares.October 22 at 9:57 AM | marketscreener.comMUnited Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of StockOctober 21, 2026 | insidertrades.comInsider Selling: United Therapeutics (NASDAQ:UTHR) EVP Sells 8,300 Shares of Company StockOctober 17, 2026 | insidertrades.comSee More Headlines UTHR Stock Analysis - Frequently Asked Questions How have UTHR shares performed this year? United Therapeutics' stock was trading at $487.25 on January 1st, 2026. Since then, UTHR shares have increased by 20.6% and is now trading at $587.50. How were United Therapeutics' earnings last quarter? United Therapeutics Corporation (NASDAQ:UTHR) released its quarterly earnings data on Wednesday, August, 5th. The biotechnology company reported $7.27 EPS for the quarter, beating analysts' consensus estimates of $6.86 by $0.41. The company's quarterly revenue was down 1.9% on a year-over-year basis. Read the conference call transcript. Is United Therapeutics buying back stock? United Therapeutics' Board of Directors initiated a share buyback plan on Thursday, October 22nd 2026, which permits the company to buy back $2,000,000,000 in shares, according to EventVestor. This means that the company could reacquire up to 8.3% of its shares through open market purchases. Shares buyback plans are typically a sign that the company's management believes its shares are undervalued. Who are United Therapeutics' major shareholders? Top institutional shareholders of United Therapeutics include Robeco Institutional Asset Management B.V. (0.34%), Assenagon Asset Management S.A. (0.16%), Atwood & Palmer Inc. (0.14%) and Apollon Wealth Management LLC (0.05%). Insiders that own company stock include Martine A Rothblatt, Paul A Mahon, Richard Giltner, James Edgemond, Ray Kurzweil, Tommy G Thompson, Nilda Mesa, Judy D Olian, Christopher Causey, Raymond Dwek, Christopher Patusky, Jan Malcolm, Michael Benkowitz and Louis W Sullivan. View institutional ownership trends. How do I buy shares of United Therapeutics? Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of United Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that United Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Broadcom (AVGO), Bristol Myers Squibb (BMY), Regeneron Pharmaceuticals (REGN), Gilead Sciences (GILD) and Micron Technology (MU). Company Calendar Last Earnings8/05/2026Today10/25/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 3 weeks, UTHR's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:UTHR CIK1082554 Webwww.unither.com Phone(301) 608-9292Fax301-608-9291Employees1,400Year Founded1996Price Target and Rating Average Price Target for United Therapeutics$650.43 High Price Target$735.00 Low Price Target$368.00 Potential Upside/Downside+10.7%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)$27.95 Trailing P/E Ratio21.02 Forward P/E Ratio22.54 P/E Growth4.26Net Income$1.33 billion Net Margins41.56% Pretax Margin49.87% Return on Equity20.18% Return on Assets17.98% Debt Debt-to-Equity RatioN/A Current Ratio5.73 Quick Ratio5.41 Sales & Book Value Annual Sales$3.18 billion Price / Sales7.92 Cash Flow$32.99 per share Price / Cash Flow17.81 Book Value$164.81 per share Price / Book3.56Miscellaneous Outstanding Shares42,890,000Free Float39,202,000Market Cap$25.20 billion OptionableOptionable Beta0.49 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:UTHR) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersWhy tech stocks are deadAI skeptics see dot-com era warning signs, and they have a point. But the real opportunity may not be in the b...Porter & Company | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredThe $100 Stock Behind Elon's Next MoveA small, publicly traded supplier trading under $100 a share has reportedly worked alongside Elon Musk for mor...Paradigm Press | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding United Therapeutics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share United Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
